{"organizations": [], "uuid": "8194b8a98cc4a65d32bafa1101938f42c84379d0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-promis-neurosciences-product-candi/brief-promis-neurosciences-product-candidate-for-alzheimers-disease-shows-potential-for-improved-therapeutic-potency-idUSFWN1PI0SY", "country": "US", "domain_rank": 408, "title": "BRIEF-Promis Neurosciences Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T14:50:00.000+02:00", "replies_count": 0, "uuid": "8194b8a98cc4a65d32bafa1101938f42c84379d0"}, "author": "", "url": "https://www.reuters.com/article/brief-promis-neurosciences-product-candi/brief-promis-neurosciences-product-candidate-for-alzheimers-disease-shows-potential-for-improved-therapeutic-potency-idUSFWN1PI0SY", "ord_in_thread": 0, "title": "BRIEF-Promis Neurosciences Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency", "locations": [], "entities": {"persons": [], "locations": [{"name": "aducanumab", "sentiment": "none"}], "organizations": [{"name": "brief-promis neurosciences product candidate", "sentiment": "negative"}, {"name": "promis neurosciences inc", "sentiment": "none"}, {"name": "improved therapeutic potency reuters staff", "sentiment": "none"}, {"name": "alzheimer", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 51 PM / in 10 minutes BRIEF-Promis Neurosciences Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency Reuters Staff 1 Min Read \nJan 23 (Reuters) - Promis Neurosciences Inc: \n* PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FOR ALZHEIMER‘S DISEASE SHOWS POTENTIAL FOR IMPROVED THERAPEUTIC POTENCY VERSUS OTHER AMYLOID BETA-DIRECTED ANTIBODIES \n* PROMIS - ‍IN COMPARISON TO ADUCANUMAB, PMN310 SHOWED SIGNIFICANTLY GREATER BINDING TO BRAIN MATERIAL FROM AD PATIENTS WITH TOXIC AΒ OLIGOMERS​ \n* PROMIS NEUROSCIENCES INC - “‍AFFINITY MATURATION OF PMN310 IS ONGOING AND MAY RESULT IN AN EVEN GREATER ADVANTAGE WITH PMN310”​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-23T14:50:00.000+02:00", "crawled": "2018-01-23T15:09:20.030+02:00", "highlightTitle": ""}